Anagrelid hæmmer cyklisk AMP fosfodiesterase III, og på grund af dets positive, inotopiske virkninger anbefales en kardiovaskulær undersøgelse forud for behandlingen (inklusive yderligere undersøgelse som ekkokardiografi, elektrokardiogram).
Anagrelide is an inhibitor of cyclic AMP phosphodiesterase III and because of its positive inotropic effects, a pre- treatment cardiovascular examination (including further investigation such as echocardiography, electrocardiogram) is recommended.